SmartPeptide
Start Free
SkinLimited human evidence

Argireline (Acetyl Hexapeptide-8)

Synthetic hexapeptide (Glu-Glu-Met-Gln-Arg-Arg) marketed as a topical 'botox alternative.' Theoretically interferes with SNARE complex formation, reducing neurotransmitter release at neuromuscular junctions. Topical formulations are widely sold in cosmetics. Effect size is modest at best in published trials.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Small topical trials show measurable but modest reduction in wrinkle depth and frequency with 10% Argireline formulations over 4-8 weeks. Effect size is far smaller than botulinum toxin injection. Skin penetration is limited — most of the topical dose doesn't reach target.

What's still experimental

Optimal formulation, delivery enhancement (e.g. liposomal), and combination with other topical actives. Injectable Argireline is NOT a thing — only topical.

Anecdotal / community reports

Wide consumer use. Subjective benefits vary; many users notice little visible change. Cosmetic-industry marketing often overstates the effect size.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Argireline (Acetyl Hexapeptide-8)”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Argireline (Acetyl Hexapeptide-8)”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C46H59N7O9

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
50
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
6 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "argireline"

Europe PMC — 9,037 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
16,130
all years
Last 5 years
5,066
recent activity
Open access
14,866
freely readable
OA share
92%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “argireline OR acetyl hexapeptide-8 OR acetyl hexapeptide-3” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
32,287
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China688 works
  • National Institutes of Health206 works
  • Japan Society for the Promotion of Science117 works
  • National Key Research and Development Program of China89 works
  • Ministry of Education, Culture, Sports, Science and Technology79 works
  • National Science Foundation64 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 48 preprints indexed by Europe PMC.

Known risks

Topical use is generally low-risk. Skin irritation possible. Theoretical concerns about systemic neuromuscular effects from topical absorption are unsupported by data — Argireline penetrates poorly.

Reported side effects

Mild skin irritation, redness. Most users tolerate topical formulations well.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “Argireline (Acetyl Hexapeptide-8)”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

OTC topical. No clinician supervision needed for normal cosmetic use.

Questions for your clinician

  • Should I consider botulinum toxin injection for stronger evidence-based results?
  • What other topical actives have better evidence (retinoids, vitamin C)?
  • Is the product I'm considering at a meaningful concentration (5-10%)?

Editorially curated references

Discussions about Argireline (Acetyl Hexapeptide-8)

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Argireline (Acetyl Hexapeptide-8) discussions Native, moderated, no buying or selling